Idiopathic Hypersomnia
Idiopathic Hypersomnia (IH) is a rare sleep disorder that causes excessive daytime sleepiness even after a full night's sleep, making it difficult for individuals to stay awake and alert during the day.
Idiopathic Hypersomnia: ALKS 2680 Study
We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently pregnant or breastfeeding?
- Do you have another sleep disorder that affects your sleep-wake cycle?
- Have you had any major health issues or surgeries that could affect your safety in this study?
- Are you currently enrolled in another clinical study or have you used any investigational drug or device in the last 30 days?
- Have you been diagnosed with idiopathic hypersomnia (IH) in the last 10 years?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Alks 2680
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Anima
Research Center
Alken, Belgium
Pneumocare
Medical Research Center
Jambes, Belgium
Vseobecna Fakultni Nemocnice V Praze
Neurologická klinika
Prague, Czechia
Sponsor: Alkermes Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.